"Higher response rate seen with T-VEC in advanced melanoma" - Andrew Alexis, MD
Talimogene laherparepvec (T-VEC) is a novel therapeutic option for patients with metastatic melanoma that not only selectively targets melanoma cells (via genetically modified herpes simplex 1) but also, enhances systemic antitumor immune responses (by producing granulocyte macrophage colony-stimulating factor). The results of this study are exciting in that they offer hope to patients with inoperable melanomas – a population with limited effective treatment options and low response rates to currently available therapies.
- Andrew Alexis, MD, MPH, Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Director, The Skin of Color Center at Mount Sinai, Site Chair, Department of Dermatology, Mount Sinai St. Luke’s and Mount Sinai West